AZN.L in “America Imports the World's Drug Prices”
AstraZeneca PLC
Its globally diversified oncology portfolio is exposed both to lower US prices and pressure to raise prices elsewhere.
AZN.L impact map — “America Imports the World's Drug Prices”
How this story travels from the headline to AZN.L’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading AZN.L impact map…
Price history, marked with story events
Jul 20, 2026 – Oct 19, 2026 · 32 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
America Imports the World's Drug Prices
US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
BEAR side — Its globally diversified oncology portfolio is exposed both to lower US prices and pressure to raise prices elsewhere.
Read the full America Imports the World's Drug Prices storyBull side
1 story- China Becomes Pharma's Global R&D Engine
AZN.L in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
AstraZeneca's extensive Chinese presence and active business development provide early access to emerging local innovation.
Bear side
2 stories- Viewing
AZN.L in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Its globally diversified oncology portfolio is exposed both to lower US prices and pressure to raise prices elsewhere.
- The Patent Cliff Sparks a Biotech Land Grab
AZN.L in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
AstraZeneca must offset approaching exclusivity losses across several major medicines, creating pressure to keep buying or licensing increasingly expensive late-stage assets.